Vivos (RDGL) Gains from Investment Securities (2017)
Vivos' (RDGL) quarterly Gains from Investment Securities came in at $2800.0 in Q2 2017.
Vivos (RDGL) Gains from Investment Securities (2017) Analysis & Trends
Vivos has disclosed Gains from Investment Securities across 1 years of filings, most recently posting $2800.0 for Q2 2017.
- Gains from Investment Securities for Q2 2017 came in at $2800.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2018 was $2800.0 (changed N/A YoY), and the FY2017 annual result was $2800.0, changed N/A from the prior year.
- Gains from Investment Securities came in at $2800.0 for Q2 2017 at Vivos.
- In the past five years, Gains from Investment Securities ranged from a high of $2800.0 in Q2 2017 to a low of $2800.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Vivos | - | - | -3,105.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 2,800.00 |
| Jun 30, 2017 | 2,800.00 |